Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2021

View Archived Issues

NKMAX studies SNK-01 with chemotherapy and cetuximab in advanced NSCLC

New phase II trial evaluates BDB-001 for PD-(L)1 refractory solid tumors

Progress in the search for opioid multitarget ligands for persistent pain relief

ECM1a isoform plays a tumorigenic role and confers cancer cell cisplatin resistance

Deep intronic F9 gene variants linked to hemophilia B

Enteric HDL shown to prevent liver injury via portal vein

Targeting TYMP as potential new therapeutic strategy against COVID-19

Sunshine Lake Pharma, Dongguan Hec New Drug Research and Development patent RORgammaT antagonists

Multiple kinase inhibitors identified at Medshine Discovery

New glucagon-like peptide 1 derivatives identified at Gan & Lee Pharmaceuticals

Heterodimeric interference among IKZF family proteins results in inborn errors of immunity

Denali reports interim data from phase I/II study of DNL-310 in Hunter's syndrome

Shionogi initiates phase I trial in Japan of 3CL protease inhibitor S-217622 for COVID-19

Innovent initiates phase Ia study of anti-PD-1/TIGIT bispecific antibody IBI-321

DSMB reviews phase Ib part of ILIAD study of ilixadencel with pembrolizumab in advanced cancers

New mouse model created for cerebral venous sinus thrombosis

Cortexyme selects 3CLpro inhibitor COR-803 to treat coronavirus infections

FDA clears IND for phase I study of NT-I7 for Kaposi sarcoma

MediWound's MW-005 studied in clinical trials for BCC and nonmelanoma skin cancers

Aurion releases preliminary findings from study of cell therapy for corneal endothelial disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...